Roth MKM analyst Jonathan Aschoff notes that on Tuesday, Ipsen (IPSEY) received FDA approval in first-line mPDAC for Onivyde in combination with 5-FU/leucovorin and oxaliplatin — NALIRIFOX. This approval is the first first-line FDA approval in mPDAC since the mPACT trial that led to the 2013 approval of gemcitabine/Abraxane, which served as the control arm for Ipsen’s NALIRIFOX trial. The firm believes that the earlier Phase 1/2 results for NALIRIFOX in first-line mPDAC give investors reason for optimism for SBP-101’s pivotal trial when viewed in light of Panbela Therapeutics’ (PBLA) Phase 1/1b results in first-line mPDAC. Roth has a Buy rating on Panbela Therapeutics with a price target of $25 on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PBLA:
- Panbela Therapeutics Issues New Shares Post-Warrant Exercise
- Panbela Therapeutics Completes Common Stock Offering
- Panbela Announces Closing of Approximately $9.0 Million Public Offering
- Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
- Panbela Therapeutics Announces Public Offering Pricing
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue